SCHEMBL5654051

SCHEMBL5654051

Cc1ccc2nc(C)c(C)c(C)c2c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.39
MAPK1 P28482 1/20 0.39
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2A6 P11509 1/20 0.33
TSHR P16473 1/20 0.33
PDE10A Q9Y233 1/20 0.33
PDE3B Q13370 4/20 0.33
PDE3A Q14432 4/20 0.33
PDE2A O00408 1/20 0.33
P2RY12 Q9H244 1/20 0.33
CDC7 O00311 1/20 0.33
DBF4 Q9UBU7 1/20 0.33
IDO1 P14902 1/20 0.32
GPR3 P46089 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918406 0.87 MAPT (0.37) MAPTKDM4ECYP1A2PDE10ACDC7
SCHEMBL3885065 0.77 ELANE (0.47)
SCHEMBL18672400 0.77 MAPT (0.37) MAPTKDM4EMAPK1CYP1A2CYP2A6
SCHEMBL29791541 0.77 ELANE (0.47)
SCHEMBL9623175 0.76 NQO2 (0.34) MAPTKDM4ENOS3NOS1NOS2
SCHEMBL4029524 0.74 DHFR (0.49) MAPTPDE3ATDP1ALDH1A1
SCHEMBL8768322 0.74 PDE3B (0.49) MAPTKDM4EMAPK1CYP1A2PDE10A
SCHEMBL8875011 0.73 PDE10A (0.47) KDM4EMAPK1CYP1A2CYP2A6TSHR
SCHEMBL27704550 0.73 PARP10 (0.39) MAPTKDM4EPDE3BPDE3AALDH1A1
Hydrochloric Acid SCHEMBL6600020 0.73 DHFR (0.47) MAPTPDE3ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101018552-A Intracellular receptor modulator compounds and methods LIGAND PHARM INC (US) 2007-08-15 CN claimed
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. 2007-11-01 US disclosed
CN-101018552-A Intracellular receptor modulator compounds and methods LIGAND PHARM INC (US) 2007-08-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS CASR, GRK2, RYR2 MAPT 3411/4885KDM4E 4073/4885MAPK1 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.